N,6,6-trimethylhept-2-en-4-yn-1-amine

We are N,6,6-trimethylhept-2-en-4-yn-1-amine CAS:83554-69-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: N,6,6-trimethylhept-2-en-4-yn-1-amine
CAS.NO: 83554-69-2
Synonyms:
(2E)-N,6,6-TRIMETHYL-2-HEPTEN-4-YN-1-AMINE
(E)-N,6,6-Trimethylhept-2-en-4-in-1-ylamine
trans-N-(6,6-dimethylhept-2-en-4-ynyl)-methylamine
2-Hepten-4-yn-1-amine,N,6,6-trimethyl-,(2E)
2-Hepten-4-yn-1-amine,N,6,6-trimethyl-,(E)
N-(6,6-dimethyl-hept-2-en-4-ynyl)methylamine
N-(6,6-dimethyl-2-hepten-4-ynyl)methylamine
(E)-N,6,6-trimethyl-2-hepten-4-yn-1-amine

Molecular Formula: C9H13Cl
Molecular Weight:  156.65300

Physical and Chemical Properties:
Density:0.9±0.1 g/cm3
Boiling point: 207.5±23.0 °C at 760 mmHg
Melting point: /
Flash point:74.7±18.0 °C
Refractive index:1.475

Specification:
Appearance: Light Yellow Liquid
Purity:≥98%
Moisture:≤0.2%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Terbinafine  CAS: 91161-71-6
Intermediates of Terbinafine hydrochloride CAS:78628-80-5

Related News: Active pharmaceutical ingredients or APIs can be defined as the chemicals used to manufacture pharmaceutical drugs.(S)-benzyl 2-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate CAS:1420478-88-1 By drawing these distinctions between APIs and the drugs themselves, manufacturers are able to specialize and pharmacists able to align generic equivalents with brand names.2-(2-aminopropan-2-yl)-N-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-6-oxopyrimidine-4-carboxamide Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).4-hydroxy-3,5-dimethylbenzaldehyde The drug review center will establish a registration platform and database for APIs, pharmaceutical excipients and pharmaceutical packaging materials, which means that the domestic drug substance DMF system is expected to be gradually implemented.Active Pharmaceutical Ingredients (APIs): Pharmaceutical active ingredients, which are the basic substances that constitute the pharmacological effects of pharmaceuticals, and are prepared by chemical synthesis, plant extraction, or biotechnology.